Evolocumab
Indication
Prevention of cardiac events in patients with CHD and a history of ACS, in combination with a statin
Evolocumab for NICE TA394
Black
Brand:
Repatha®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Cardiovascular system
Background
The evidence for Evolocumab in the setting of patients with CHD and a history of ACS, in combination with a statin was reviewed however this did not provide adequate cost effectiveness data to allow use in patients in addition to those covered by NICE TA394
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: